drugset / Trial / NCT05166837
The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A randomized, double-blind, placebo-controlled, single-ascending dose Phase Ⅰa study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of STSA-1002 following intravenous infusion in healthy subjects
Timeline
- Start
- 2022-01-10
- Primary completion
- 2023-01-12
- Completion
- 2023-01-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GREZIPRUBART | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | GREZIPRUBART | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | GREZIPRUBART | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | GREZIPRUBART | Monoclonal antibody | 20 mg/kg | Intravenous |
| Subject | GREZIPRUBART | Monoclonal antibody | 30 mg/kg | Intravenous |
Indications
No indication recorded.